Immunomodulatory effect of morphine: Therapeutic implications

Expert Opinion on Drug Safety

Volumn 4, Issue 4, 2005, Pages 669-675

  Dinda, Amit ^a   Gitman, Michael ^a   Singhal, Pravin C ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Immunomodulation; Macrophage; Morphine; Opiate; Renal fibrosis; T cell

Indexed keywords

CARBOPLATIN; IMMUNOMODULATING AGENT; KAPPA OPIATE RECEPTOR AGONIST; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; PACLITAXEL;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; CANCER PAIN; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DIARRHEA; DROWSINESS; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG EFFECT; DYSPNEA; ENTERITIS; HEAD AND NECK CARCINOMA; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; LYMPHOKINE ACTIVATED KILLER CELL; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEPHRITIS; NONHUMAN; ODDI SPHINCTER; PRURITUS; RENAL PROTECTION; REVIEW; SHORT BOWEL SYNDROME; SPASTICITY; SQUAMOUS CELL CARCINOMA; URINE RETENTION; WOUND HEALING;

ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; MACROPHAGES; MORPHINE; NARCOTICS; T-LYMPHOCYTES;

EID: 21744455746     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.4.669     Document Type: Review

References (75)

1. WAY EL: History of opiate use in the Orient and the United States. Ann. NY. Acad. Sci. (1982) 398:12-23.
2. KANJHAN R: Opioids and pain. Clin. Exp. Pharmacol. Physiol. (1995) 22(6-7):397-403.
3. PRZEWLOCKI R, PRZELOCKA B: Opioids in chronic pain. Eur. J. Pharmacol. (2001) 429(1-3):79-91.
4. VON ZASTROW M: A cell biologist's perspective on physiological adaptation to opiate drugs. Neuropharmacology (2004) 47(Suppl. 1):286-292.
5. FRIEDMAN H, NEWTON C, KLEIN TW: Microbial infections, immunomodulation, and drugs of abuse. Clin. Microbiol. Rev. (2003) 16:209-219.
6. McCARTHY LM, WETZEL JKS, EISENSTEIN TK et al.: Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. (2001) 62:111-123.
7. SHARP BM, ROY S, BIDLACK JM: Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol. (1998) 83:45-56.
8. GRIMM MC, BEN-BARUCH A, TAUB DD et al.: Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J. Exp. Med. (1998) 188:317-325.
9. CHAO CC, MOLITOR TW, CLOSE K et al.: Morphine inhibits the release of tumor necrosis factor in human peripheral blood mononuclear cell cultures. Int. J. Immunopharmacol. (1993) 15:447-453.
10. LYSLE DT, COUSSON ME, WATTS VJ et al.: Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. (1993) 265:1071-1078.
11. ROY S, BARKE RA, LOH HH: MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Brain Res. Mol. Brain Res. (1998) 61:190-194.
12. PELLIS NR, HARPER C, DAFNY N: Suppression of the induction of delayed hypersensitivity in rats by repetitive morphine treatments. Exp. Neurol. (1986) 93:92-97.
13. WEBER RJ, PERT A: The periaqueductal gray matter mediates opiate-induced immunosuppression. Science (1989) 245:188-190.
14. PATEL K, BHASKARAN M, DANI D et al.: Role of heme oxygenase- 1 in morphine-modulated apoptosis and migration of macrophages. J. Infect. Dis. (2003) 187:47-54.
15. SINGHAL PC, BHASKARAN M, PATEL J et al.: Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis. J. Immunol. (2002) 168:4025-4033.
16. SINGHAL PC, KAPASI AA, FRANKI N et al.: Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta. Immunology (2000) 100:57-62.
17. SINGHAL PC, SHARMA P, KAPASI AA et al.: Morphine enhances macrophage apoptosis. J. Immunol. (1998) 160:1886-1893.
18. BHAT RS, BHASKARAN M, MONGIA A et al.: Morphine-induced macrophage apoptosis: oxidative stress and strategies for modulation. J. Leukoc. Biol. (2004) 75:1131-1138.
19. SZABO I, ROJAVIN M, BUSSIERE JL et al.: Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.J. Pharmacol. Exp. Ther. (1993) 267:703-706.
20. BRYANT HU, BERNTON EW, KENNER JR et al.: Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment. Endocrinology (1991) 128:3253-3258.
21. WANG J, CHARBONEAU R, BALASUBRAMANIAN S et al.: Morphine modulates lymph node-derived T lymphocyte function: role of caspase-3, -8, and nitric oxide. J. Leukoc. Biol. (2001) 70:527-536.
22. ROY S, BALASUBRAMANIAN S, SUMANDEEP S et al.: Morphine directs T cells toward T(H2) differentiation. Surgery (2001) 130:304-309.
23. GLARE PA, WALSH TD: Clinical pharmacokinetics of morphine. Ther. Drug Monit. (1991) 13(1):1-23.
24. HASSELSTROM J, SAWE J: Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin. Pharmacokinet. (1993) 24(4):344-354
25. CHRISTRUP LL: Morphine metabolites. Acta Anaesthesiol. Scand. (1997) 41 (1 Pt 2):116-122.
26. WORLD HEALTH ORGANIZATION: Cancer pain relief: with a guide to opioid availability. 2nd Ed. Geneva: World Health Organization 1996.
27. AMERICAN SOCIETY OF ANESTHESIOLOGISTS TASK FORCE ON ACUTE PAIN MANAGEMENT: Practice guidelines for acute pain management in the perioperative setting. Anesthesiology (2004) 100(6):1573-1581.
28. BREALL JA, AROESTY JM, SIMONS M: Overview of the management of unstable angina and acute non-ST elevation (non-Q wave) myocardial infarction. UpToDate online vol.12.3 (2005).
29. ABERNETHY AP, CURROW DC, FRITH P et al.: Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ (2003) 327(7414):523-528.
30. FORAL PA, MALESKER MA, HUERTA G et al.: Nebulized opioids use in COPD. Chest (2004) 125(2):691-694.
31. POLOSA R, SIMIDCHIEV A, WALTERS EH: Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst. Rev. (2002) 3:CD002872.
32. BOLSER DC, HEY JA, CHAPMAN RW: Influence of central antitussive drugs on the cough motor pattern. J. Appl. Physiol. (1999) 86(3):1017-1024.
33. CHUNG KF, CHANG AB: Therapy for cough: active agents. Pulm. Pharmacol. Ther. (2002) 15(3):335-338.
34. RUTHERFOLD RM, AZHER T, GILMARTIN JJ: Dramatic response to nebulized morphine in an asthmatic patient with severe chronic cough. Ir. Med. J. (2002) 95(4):113-114.
35. CORAZZIARI E: Role of opioid ligands in the irritable bowel syndrome. Can. J. Gastroenterol. (1999)13 (Suppl. A):71-75.
36. IPPOLITI C: Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am. J. Health Syst. Pharm. (1998) 55(15):1573-1580.
37. SILVA AC, FRIESE JL, HARA AK et al.: MR cholangiopancreatography: improved ductal distention with intravenous morphine administration. Radiographics (2004) 24(3):677-687.
38. SONO BM, MANI RM, OO T et al.: Treatment of spasticity in a spinal cord-injured patient wth nitrathecal morphine due to intrathecal baclofen tolerance - a case report and review of literature. Spinal Cord (2003) 41 (10):586-589.
39. ROGANO LA, GREVE JM, TEIXEIRA MJ: Use of intrathecal morphine infusion for spasticity. Arq. Neuropsiquiatr. (2004) 62:403-405.
40. STEFANO GB, SALZET B, FRICCHIONE GL: Enkelytin and opioid peptide association in invertebrates and vertebrates: immune activation and pain. Immunol. Today (1998) 19(6):265-268.
41. STEFANO GB, SCHARRER B, SMITH EM et al.: Opioid and opiate immunoregulatory processes. Crit. Rev. Immunol. (1996) 16(2):109-144.
42. ZAGON IS, GOODMAN SR, McLAUGHLIN PJ: Characterization of zeta (zeta): a new opioid receptor involved in growth. Brain Res. (1989) 482(2):297-305.
43. BISIGNANI GJ, McLAUGHLIN PJ, ORDILLE SD et al.: Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor. J. Urol. (1999) 162(6):2186-2191.
44. MCLAUGHLIN PP, LEVIN RJ, ZAGON IS: Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int. J. Oncol. (1999) 14(5):991-998.
45. ZAGON IS, HYTREK SD, LANG CM et al.: Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer. Am. J. Physiol. (1996) 271(3 Pt 2):R780-R786.
46. ZAGON IS, HYTREK SD, SMITH JP et al.: Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett. (1997) 112(2):167-175.
47. ZAGON IS, VERDERAME MF, MCLAUGHLIN PJ: The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. (2002) 38:351-376.
48. ZAGON IS, VERDERAME MF, ALLEN SS et al.: Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res. (2000) 856:75-83.
49. MCLAUGHLIN PJ, JAGLOWSKI JR, VERDERAME MF et al.: Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int. J. Oncol. (2005) 3:809-816.
50. PAGE GG, BEN-ELIYAHU S, YIRMIYA R et al.: Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain (1993) 54(1):21-28.
51. PAGE GG, McDONDALD JS, BEN-ELIYAHU S: Pre-operative versus postoperative administration of morphine: impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery. Br. J. Anaesth. (1998) 81(2):216-23.
52. RASMUSSEN M, ZHU W, TONNESEN J et al.: Effects of morphine on tumour growth. Neuro. Endocrinol. Lett. (2002) 23(3):193-198.
53. SUEOKA E, SUEOKA N, KAI Y et al.: Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF-kappaB activation. Biochem. Biophys. Res. Commun. (1998) 252(3):566-570.
54. WELTERS ID, FIMIANI C, BILFINGER TV et al.: NF-kappaB, nitric oxide and opiate signaling. Med. Hypotheses (2000) 54(2):263-268.
55. BARG J, BELCHEVA MM, ZIMLICHMAN R et al.: Opioids inhibit endothelin-mediated DNA synthesis, phosphoinositide turnover, and Ca2+ mobilization in rat C6 glioma cells. J. Neurosci. (1994) 14(10):5858-5864.
56. TEGEDER I, GROSCH S, SCHMIDTKO A et al.: G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. (2003) 63(8):1846-1852.
57. PROVINCIALI M, DiSTEFANO G, RAFFAELI W et al.: Evaluation of NK and LAK cell activities in neoplastic patients during treatment with morphine. Int. J. Neurosci. (1991) 59(1-3):127-133.
58. VALLEJO R, de LEON-CASASOLA O, BENYAMIN R: Opioid therapy and immunosuppression: a review. Am. J. Ther. (2004) 11(5):354-365.
59. WANG TL, CHANG H, HUNG CR et al.: Attenuation of neutrophil and endothelial activation by intravenous morphine in patients with acute myocardial infarction. Am. J. Cardiol. (1997) 80(12):1532-1535.
60. WANG TL, CHANG H, HUNG CR et al.: Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. Cardiovasc. Res. (1998) 40(3):557-563.
61. PEART JN, GROSS GJ. Morphine-tolerant mice exhibit a profound and persistent cardioprotective phenotype. Circulation (2004) 109(10):1219-1222.
62. SINGHAL P, KAPASI A, REDDY K et al.: Opiates promote T cell apoptosis through JNK and caspase pathway. Adv. Exp. Med. Biol. (2001) 493:127-135.
63. ROY S, WANG J, GUPTA S et al.: Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet. J. Neuroimmunol. (2004) 147(1-2):78-81.
64. NELSON CJ, DYKSTRA LA, LYSLE DT: Comparison of the time course of morphine's analgesic and immunologic effects. Anesth. Analg. (1997) 85(3):620-626.
65. RAGHAVENDRA V, RUTKOWSKI MD, DELEO JA: The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. (2002) 22:9980-9989.
66. ALONZO NC, BAYER BM: Antagonism of N-methyl-D-aspartate receptors reduces the vulnerability of the immune system to stress after chronic morphine. J. Pharmacol. Exp. Ther. (2003) 307(2):793-800.
67. ALLOLIO B, SCHULTE HM, SCHULTE U et al.: Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta. Endocrinol. (Copenhagen) (1987)114:509-514.
68. BOUMPAS DT, CHROUSOS GP, WILDER RL et al.: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. (1993) 119:1198-1208.
69. KASAHARA T, SAKURAI Y, AMEMIYA M et al.: Suppressive effects of central opioids on delayed type hypersensitivity to trinitrochlorobenzene: comparative study with morphine and electroacupuncture. In vivo (1995) 9(3):177-181.
70. WALKER JS: Anti-inflammatory effects of opioids. Adv. Exp. Med. Biol. (2003) 521:148-160.
71. MOUSA SA: Morphological correlates of immune-mediated peripheral opioid analgesia. Adv. Exp. Med. Biol. (2003)521:77-87.
72. TEGEDER I, GEISSLINGER G: Opioids as modulators of cell death and survival-unraveling mechanisms and revealing new indications. Pharmacol. Rev. (2004) 56(3):351-369.
73. SINGHAL PC, SHARMA P, SANWAL V et al.: Morphine modulates proliferation of kidney fibroblasts. Kidney Int. (1998) 53(2):350-357.
74. CHO CH, WU KK, WU S et al.: Morphine as a drug for stress ulcer prevention and healing in the stomach. Eur. J. Pharmacol. (2003) 460(2-3):177-182.
75. SEMERDZHIEV Y, UPADHYA P, FRANKI N et al.: Morphine Modulates Renal Interstitial Fibrosis: A Pharmacologically Modified UUO Model. J. Am. Soc. Nephrol. (2004) 15:696A.